Table 1 Clinical summary of patients
Patient/sex/age | HCQ cumulative dose (g) | Body mass index | HCQ indication | Follow-up after HCQ cessation (months) | HCQ cessation VA | Most recent VA | Symptoms at HCQ cessation | Symptoms at follow-up | Progression after HCQ cessation? |
|---|---|---|---|---|---|---|---|---|---|
E1/F/57 | 730 | a | Psoriatic arthritis | 13 | OD:20/20 OS:20/20 | OD:20/20 OS:20/20 | None | None | Yes (OCT, HVF) |
E2/F/74 | 890 | a | SLE | 13 | OD:20/30 OS:20/40 | OD:20/40 OS:20/40 | Decreased near vision | Decreased near vision | Yes (OCT) |
E3/F/69 | 584 | 51 | RA | 56 | OD:20/25 OS:20/25 | OD:20/30 OS:20/30 | None | None | Yes (OCT, HCF) |
E4/F/61 | 438 | 26 | RA | 12 | OD:20/25 OS:20/25 | OD:20/25 OS:20/25 | Floaters | None | No |
E5/F/65 | 949 | 17 | RA | 42 | OD:20/20 OS:20/20 | OD:20/20 OS:20/20 | Floaters | None | Yes (OCT, HVF) |
O1/F/48 | 2210 | a | SLE | 18 | OD:20/30 OS:20/40 | OD:20/30 OS:20/30 | None | None | Yes (OCT) |
O2/F/65 | 4380 | 24 | RA | 36 | OD:20/20 OS:20/20 | OD:20/20 OS:20/20 | Floaters | Floaters | Yes (OCT) |
O3/F/62 | 1022 | 24 | RA | 42 | OD:20/50 OS:20/60 | OD:20/40 OS:20/50 | Blurry vision | Blurry vision | No |
O4/F/63 | 2482 | a | SLE | 36 | OD:20/25 OS:20/25 | OD:20/25 OS:20/25 | Floaters | Flashes | Yes (OCT) |
O5/F/69 | 1550 | a | SLE | 12 | OD:20/25 OS:20/25 | OD:20/25 OS:20/25 | Glare | Glare, floaters | No |
O6/F/67 | 1933 | 24 | SLE | 12 | OD:20/25 OS:20/25 | OD:20/25 OS:20/25 | None | None | Yes (OCT) |
O7/F/68 | 1048 | 26 | RA | 36 | OD:20/20 OS:20/30 | OD:20/30 OS:20/40 | None | Decreased near vision | Yes (OCT, FP) |
O8/F/75 | 2628 | 24 | RA | 12 | OD:20/25 OS:20/25 | OD:20/25 OS:20/25 | None | Decreased near vision | Yes (OCT) |
S1/F/63 | 1030 | 23 | RA | 36 | OD:20/400 OS:20/100 | OD:20/400 OS:20/150 | Decreased central vision | Decreased central vision | Yes (OCT) |
S2/F/76 | 1679 | 19 | RA | 14 | OD:20/150 OS:20/50 | OD:20/100 OS:20/100 | Blurry vision | Blurry vision | No |